


TRANSITION TO THE RENEWED NATIONAL CERVICAL SCREENING PROGRAM

Women of any age with Existing Abnormalities* (cytology or histopathology)



* Prior to December 2017

** A woman who has been treated for HSIL (CIN2/3) should have a co-test (HPV and LBC) performed at 12 months after treatment, and annually thereafter, until both tests are negative on two consecutive occasions, when she can return to routine 5-yearly screening

Until sufficient data become available that may support a policy decision that cessation of testing is appropriate